Brucella Vaccine 2026

Dear Colleagues,

Zoonotic diseases are caused by animals that transmit the pathogen to humans. Brucella species are Gram-negative intracellular bacteria associated with farm animal brucellosis, in which they cause abortion at third trimester of pregnancy and, then after, contaminating the colostrum and milk. Thus, the integration of these animals with the milk and meat reproduction systems is the reason for the accumulation of cluster infections in the human population, negatively impacting public health as well as the economy. Regulatory measures, such as pasteurizing milk and implementing animal biosecurity protocols, are essential for preventing the spread of this disease to humans. However, these measures do not stop the natural cycles of infection that occur on farms. Vaccination with live attenuated strains provides animals with cellular immune protection, helping to prevent miscarriages in pregnant animals and thus reducing the spread of the disease to naïve animals. Thus, vaccination remains the most successful method for the prevention and control of brucellosis in cattle and small ruminants, presenting a critical component of most brucellosis control and eradication programs across the world. This Special Issue invites articles that analyze vaccination policies, explore novel vaccines, and investigate animal/in vitro tissue culture models to develop the next generation of Brucella vaccines.

We look forward to receiving your contributions.

Dr. Menachem Banai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.